Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ross

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Cancers|January 11, 2025
A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug ResistanceEleni E Ladikou, Kim Sharp, Fabio A Simoes, et al.
Leukemia|November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remissionIlaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Haematologica|October 7, 2017
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndromeDeepak Singhal, Monika M Kutyna, Rakchha Chhetri, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Blood|April 2, 2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinibChan Y Cheah, Kate Burbury, Jane F Apperley, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Leukemia|September 16, 2025
Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CMLMikko Purhonen, Mikael Tatun, Katariina Luukkainen, et al.
Blood|September 2, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutationsNaranie Shanmuganathan, David T Yeung, Carol Wadham, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Cancers|January 11, 2025
A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug ResistanceEleni E Ladikou, Kim Sharp, Fabio A Simoes, et al.
Leukemia|November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remissionIlaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Haematologica|October 7, 2017
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndromeDeepak Singhal, Monika M Kutyna, Rakchha Chhetri, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Blood|April 2, 2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinibChan Y Cheah, Kate Burbury, Jane F Apperley, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Leukemia|September 16, 2025
Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CMLMikko Purhonen, Mikael Tatun, Katariina Luukkainen, et al.
Blood|September 2, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutationsNaranie Shanmuganathan, David T Yeung, Carol Wadham, et al.
Pageof 13